发明申请
US20070099955A1 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS
失效
3-PIPERIDINYLISOCHROMAN-5-OLS作为DOPAMINE AGONISTS
- 专利标题： 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS
- 专利标题（中）： 3-PIPERIDINYLISOCHROMAN-5-OLS作为DOPAMINE AGONISTS
-
申请号： US11552169申请日： 2006-10-24
-
公开(公告)号： US20070099955A1公开(公告)日： 2007-05-03
- 发明人: Gregory Shutske , Keith Harris , Kenneth Bordeau , Michael Angelastro , Stanly John , Joseph Klein , Jinqi Lu , Catherine Bomont
- 申请人： Gregory Shutske , Keith Harris , Kenneth Bordeau , Michael Angelastro , Stanly John , Joseph Klein , Jinqi Lu , Catherine Bomont
- 申请人地址： US NJ Bridgewater 08807
- 专利权人： AVENTIS PHARMACEUTICALS INC.
- 当前专利权人： AVENTIS PHARMACEUTICALS INC.
- 当前专利权人地址： US NJ Bridgewater 08807
- 主分类号： A61K31/4709
- IPC分类号： A61K31/4709 ; A61K31/452 ; C07D405/02
摘要：
The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.
公开/授权文献
- US07919508B2 3-piperidinylisochroman-5-ols as dopamine agonists 公开/授权日：2011-04-05
信息查询
IPC分类:
